Search Results
Sep 09, 2026, 08:00 ET UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA®(certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial. Ann Rheum Dis. 2025;84(7):1011-1022.Branch DW, Lim MY. How I diagnose and treat antiphospholipid syndrome in pregnancy. Blood. 2024;143(9):757-768.Lee
More news about: UCB
Sep 07, 2026, 05:42 ET Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
Q., Xiao, D., Veviorskiy, A. et al. AI-Driven Robotics Laboratory Identifies Pharmacological TNIK Inhibition as a Potent Senomorphic Agent. Aging Dis 17, 432–451 (2026). https://doi.org/10.14336/AD.2024.1492
More news about: Insilico Medicine
Sep 05, 2026, 21:30 ET Roborock, 2026 yılının ilk yarısında %27,6'lık gelir artışı kaydetti ve küresel pazardaki liderliğini pekiştirdi
açıyor.IFA 2026, İnovasyonun Bir Sonraki Aşamasını Öne ÇıkarıyorIFA 2026 fuarında Roborock, iç ve dış mekan temizliği alanındaki en son yeniliklerini sergiliyor. Şirketin yeni robot süpürgeleri ve ıslak-kuru süpürgeleri, buharlı temizlik, uyarlanabilir
More news about: Roborock
Sep 04, 2026, 02:00 ET Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026
www.argobiopharma.com.References：Pedro Giavina-Bianchi P, et al. (2011). CLINICS 66(9): 1627–1636.Aygören-Pürsün, E, et al. (2018). Orphanet J Rare Dis 13(1): 73.
More news about: Argo Biopharmaceutical Co., Ltd
Sep 03, 2026, 21:30 ET Roborock, IFA 2026'da İnsan Odaklı Temizliği Yeniden Tanımlıyor: Oturma Odasından Havuza Kadar Kapsamlı Bir Ekosistem Sunuyor
bir ıslak-kuru süpürgeden mobilyalar ve ulaşılması zor alanlar için yüksek performanslı bir kablosuz süpürgeye zahmetsizce dönüşür.Akıllı Dış Mekan Yaşamı: Roborock RockNeo Q2 LiDAR"Rocking Life" deneyimini bahçeye taşıyan Roborock RockNeo Q2 LiDAR , profesyonel çim bakımını
More news about: Roborock
Sep 03, 2026, 08:30 ET Ayble Health Joins Amazon's Health Benefits Connector to expand Virtual GI Care Access to Millions of Americans
et al. Geographic Disparities in the Supply and Demand of Gastroenterologists Across the United States: Forecasting a National Shortage. Dig Dis Sci 71, 1705–1710 (2026).
More news about: Ayble Health, Inc.
Sep 03, 2026, 03:38 ET Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress
Greece.Bialer M, et al. Epilepsia. 2026. doi:10.1002/epi.70346.Scheffer IE, et al. Epilepsia. 2025;66:1014–1023.Scheffer IE, et al. Nat Rev Dis Primers. 2024;10:61.Guerrini R, et al. Physiol Rev. 2023;103(1):433–513.ClinicalTrials.gov. NCT06719141.ClinicalTrials.gov.
More news about: H. Lundbeck A/S
Sep 03, 2026, 03:32 ET Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress
Greece.Bialer M, et al. Epilepsia. 2026. doi:10.1002/epi.70346.Scheffer IE, et al. Epilepsia. 2025;66:1014–1023.Scheffer IE, et al. Nat Rev Dis Primers. 2024;10:61.Guerrini R, et al. Physiol Rev. 2023;103(1):433–513.ClinicalTrials.gov. NCT06719141.ClinicalTrials.gov.
More news about: H. Lundbeck A/S
Sep 02, 2026, 11:55 ET Hundreds Gather in Missouri as Culture-Shifting Wellness Leader Yahki Awakened Opens Groundbreaking Health & Human Development Center
Fresh off a featured Invest Fest main-stage appearance and the surging demand for his newly released book Healing the Illusion We Call Dis-Ease: The Bible of Health, Yahki Awakened expands a growing wellness movement with a permanent home ST.
More news about: YAHKI AWAKENED
Sep 02, 2026, 03:00 ET Báo cáo mới: Dù dịch vụ điều trị đột quỵ cơ bản đã được triển khai rộng khắp cả nước, khả năng tiếp cận điều trị chuyên sâu tại Việt Nam vẫn có sự chênh lệch giữa các vùng
sự. Burden and risk factors of stroke in Vietnam from 1990 to 2021 – a systematic analysis from global burden disease 2021. J Stroke Cerebrovasc Dis. 2025 Mar;34(3):108241. doi:10.1016/j.jstrokecerebrovasdis.2025.108241
More news about: Siemens Healthineers
Sep 01, 2026, 08:15 ET DataAgent Emerges from Stealth and Launches Remediation-First Platform with $10 Million Pre-Seed Funding
DataAgent, the developer of a remediation-first Digital Immune System (DIS) for modern applications, today announced that the company has emerged from stealth with the launch of its platform and the closing of
More news about: DataAgent
Sep 01, 2026, 07:00 ET RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
Odoom A, Awere-Duodu A, Donkor ES. The Global Burden of Clostridioides difficile Infections, 2016-2024: A Systematic Review and Meta-Analysis. Infect Dis Rep. 2025 Apr 14;17(2):31. doi: 10.3390/idr17020031. PMID: 40277958; PMCID: PMC12026862.[2] Lessa FC, Mu Y, Bamberg WM, Beldavs ZG,
More news about: RedHill Biopharma Ltd.
Aug 27, 2026, 12:08 ET Huawei, 2 Eylül'de Münih'te düzenlenecek "Chase the Wild" kampanya etkinliğinde amiral gemisi giyilebilir cihazlarını tanıtacak
HUAWEI WATCH GT 7 Serisi yer alıyor. Seri, dört temel alanda daha üstün bir giyilebilir cihaz deneyimi sunuyor: cesur tasarım, geliştirilmiş dış mekân performansı, kapsamlı sağlık yönetimi ve aktif yaşam tarzlarına ayak uyduran ultra uzun pil ömrü.Bir diğer amiral gemisi
More news about: HUAWEI
Aug 27, 2026, 09:03 ET Dimensional Innovations Brings Immersive Design to UCF's Roth Tower
stadium, DI developed branding for Roth Tower along with a wayfinding program that blends UCF's football identity with its deep ties to the space industry. DI's work is part of a broader transformation of Roth Tower to add more luxury and outdoor suites as well as club space.
More news about: Dimensional Innovations
Aug 27, 2026, 02:00 ET AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
Hepatol. 2015 Dec;12(12):720-7. doi: 10.1038/nrgastro.2015.150.Gajendran M, et al. A comprehensive review and update on Crohn's disease. Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001.A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab
More news about: AbbVie
Aug 25, 2026, 07:45 ET Vascarta Outlines VAS-101's (Vasceptor®) Potential as a Non-Opioid Advance in Pain Medicine Across Sickle Cell Disease, Osteoarthritis, and Cancer
RA, Prince R, Friedman J, Gupta K. Neuroimmune signaling through spinal IL-17–TNF-α/p38 MAPK drives acute pain in sickle cell disease. J Sickle Cell Dis. 2026;3(Suppl 1):yoag020.003.
More news about: Vascarta Inc.
Aug 20, 2026, 13:49 ET Vascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease
gel (VAS-101 drug candidate) improves the microcirculation and tissue oxygenation in a rat model of sickle cell vaso-occlusive episode. J Sickle Cell Dis. 2026;3(1):yoag034.
More news about: Vascarta Inc.
Aug 20, 2026, 07:00 ET CHARTER AND COX COMMUNICATIONS COMPLETE TRANSACTION BENEFITING CUSTOMERS, LOCAL COMMUNITIES, EMPLOYEES AND SHAREHOLDERS
strategies to the Cox Communications business and the ultimate ability to realize synergies at the levels currently expected as well as potential dis-synergies; (iii) the impact of the transaction on our stock price and future operating results, including due to transaction and integration costs, increased
More news about: Charter Communications, Inc.
Aug 12, 2026, 05:59 ET Maple Leaf Foods Reports Second Quarter 2026 Financial Results
limited to the following:the benefits and impacts of the Spin-Off being realized, including the projected risks, costs, dis-synergies, and tax consequences;compliance by Maple Leaf Foods, Canada Packers and "specified shareholders", as defined in the Income Tax Act (''ITA"),
More news about: Maple Leaf Foods Inc.
Aug 11, 2026, 08:39 ET FastWave Medical Gains FDA IDE Approval to Begin Pivotal Trial of Artero™ Peripheral IVL System
laser-based coronary IVL system. FastWave was named one of Fierce Medtech's "Fierce 15" companies and MD+DI's 2025 Medtech Company of the Year, and recently expanded its international IVL patent portfolio.About FastWave Medical
More news about: FastWave Medical
Aug 11, 2026, 08:00 ET Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.[3] de Serres FJ, Blanco I, Fernández-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients:
More news about: Sentynl Therapeutics
Aug 07, 2026, 08:45 ET Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Potential Modulator of Utrophin Pathways in Duchenne Muscular Dystrophy: A Mechanistic and Transcriptomic Perspective. Degener Neurol Neuromuscular Dis. 2026;16:574524 https://doi.org/10.2147/DNND.S574524The
More news about: Atossa Therapeutics Inc
Aug 05, 2026, 09:05 ET RECKITT ANNOUNCES U.S. FDA APPROVAL OF MUCINEX® 12HR COLD & FEVER MULTI-SYMPTOM, THE FIRST OTC INNOVATION IN THE COLD & FLU CATEGORY IN 14 YEARS
2025. National Center for Health Statistics.3 Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis 2005 Nov;5(11):718–25Media Contact:Jen O'NeillReckitt (U.S)
More news about: Reckitt
Jul 30, 2026, 19:50 ET U.S. Renal Care Drives Innovation in Dialysis with Increased Availability of Medium Cut-Off Dialyzers to Support Expanded Hemodialysis
Nesrallah G. Clinical outcomes with medium cut-off versus high-flux hemodialysis membranes: A systematic review and meta-analysis. Can J Kidney Health Dis. 2022;9:20543581211067087. doi:10.1177/20543581211067087. PMID: 35083060; PMCID: PMC8785433. 7 Penny J, Salerno F, Lemoine S, McIntyre
More news about: U.S. Renal Care
Jul 30, 2026, 16:30 ET Corteva Delivers Strong 1H 2026, Raises FY 2026 Outlook, On-Track for October 1 Separation
Corteva presented as discontinued operationsBoth companies reviewed capital structure submissions with the credit rating agenciesNet dis-synergies largely offset on run-rate basis; $25 million headwind included in full-year 2026 guidance given timing of separation-related activitiesKey
More news about: Corteva Agriscience